Cenix BioScience GmbH, a leading specialist in advanced RNA interference (RNAi)-based research services has signed a research agreement with Regulus Therapeutics LLC to advance the latter's efforts in the discovery of novel therapeutic miRNA modulators.
Cenix will apply its well-established expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells. The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic potential in the area of immunology and inflammation.
Cenix BioScience GmbH is a pioneer and global leader in the convergence of high throughput (HT), genomics-driven applications of RNA interference (RNAi) with high content, multi-parametric cell-based assays. Regulus Therapeutics LLC is a biopharmaceutical company formed to discover, develop, and commercialize microRNA (miRNA) therapeutics. Regulus aspires to translate one of the most important new discoveries in biology into a novel new approach for innovative medicine and to build the leading miRNA company.